Periocular injection a feasible route for CNV treatment
March 19th 2008The size and binding characteristics of proteins are likely to influence their ability to penetrate the eye from the periocular space, but in general, proteins as large as 50-75 kDa penetrate well into the choroid but not into the retina.
Tools help clinicians identify glaucoma progression
March 15th 2008Clinicians have an array of techniques and devices available to them for assessing progression of glaucoma, and more are under development. Such tools rely on either subjective or objective measurements, with the latter generally providing more reliable results. Frequent, long-term follow-up with one or more of those approaches will increase the likelihood of detecting progression early.
Alcon releases new data for glaucoma candidate
March 14th 2008Alcon has announced positive efficacy and safety results from its second controlled proof of concept clinical study of anecortave acetate administered as an anterior juxtascleral depot in the sub-Tenon's space to reduce intraocular pressure (IOP) in patients with open-angle glaucoma.
Fewer Lucentis injections with new regimen
March 12th 2008Preliminary results of a study using the NSAID Xibrom (bromfenac ophthalmic solution 0.09%; ISTA Pharmaceuticals) therapy in combination with Lucentis (ranibizumab; Novartis) in patients with wet age-related macular degeneration (AMD), suggests that it may result in fewer injections being required.
Cataract incision size is just right thanks to new technology
March 10th 2008Incision sizes needed to remove cataracts have been significantly reduced by new technology, such as the vision enhancement system (Stellaris; Bausch & Lomb) which allows surgeons to make two 1.8 mm cuts on either side of the eye.
Resistance fuelling contact lens infections
March 4th 2008A study published in the January issue of Antimicrobial Agents & Chemotherapy, has found that the high proportion of corneal infections linked to contact lens solutions are fuelled and made resistant to treatment by the formation of a highly resistant structure of microbial cells held together with a glue-like matrix material, called biofilms.